Dermapen

THE DERMAPEN TREATMENT IS SUCCESSFUL AT TREATING A VARIETY OF SKIN PRESENTATIONS.

The Dermapen fractional micro delivery provides unparalleled collagen induction via fragmented delivery of needles into the epidermis and dermis. These micro injuries to the skin encourage and harness the power of the body’s innate ability to re-grow and repair the skin through the physiology of collagen induction. The Dermapen’s controlled precision allows for the three phases of CIT mechanics of new collagen growth to occur. The first phase begins with the release of the bodies growth factors and the further cascade of new epidermal growth, fibroblast chemo-taxis, fibroblast proliferation and matrix production. This proliferation of the body’s tissue continues to release growth factors from fibroblasts, keratinocytes and monocytes culminating in the second of three phases of CIT mechanics where collagen III, IV and I, elastin, proteoglycans, GAG’s and angiogenesis occur. The last phase of CIT and the Dermapen treatment results in the tissue remodeling process where the skins vascular matrix matures and skin tightening as well as new collagen can be seen. The body’s ability to remodel and heal itself is at the heart of this amazing product and because the process never involves heat or thermal energy or other chemicals or unnecessary trauma, the skin can quickly heal with almost zero downtime.

ASER VS. DERMAPEN

What makes Dermapen Different:
The closest technology to the Dermapen is a fractional laser.  A fractional laser “drills holes” in the skin to create a wound healing response and leaves normal tissue around the holes to be a reservoir for fibroblasts and stem cells to migrate into the holes.  Fractional radio frequency devices work on a similar principle and have many of the same side effects as fractional lasers (Yeung et al., 2012).  Dermapen also makes holes in the skin to create a wound healing response and leaves normal tissue around the holes.  These technologies have similar results, but achieve them in very different ways, and result in very different side effects profiles.  The laser uses light to char and obliterate epidermis to produce small pits which vary in diameter and depth, depending on the laser type (Erbium, YAG, CO2; nonablative vs ablative) and manufacturer.  Dermapen produces reproducible and consistent holes in the skin.
Side effects differ between technologies.  Most fractional lasers leave erythema and edema up to 48 hours after treatment.  Resultant down time is approximately 3-4 days for fractional laser treatments (Gold, 2010).  Dermapen treatments result in erythema without edema for about 24 hours.  Dermapen has none of the side effects specific to fractional lasers, such as:

  • Pain (higher in dark skined patients (Mahmoud et al., 2010)
  • Persistent erythema (Gold 2010)
  • Infections (viral and bacterial).  Facial herpes reported in 10.6% of patients in spite of antiviral prophylaxis (Naouri et al., 2011)
  • Postinflammatory hyperpigmentation in up to 18% (Vaiyavatjamai and Wattanakrai, 2011; Chan et al., 2010; Mahmoud et al., 2010; Yeung et al., 2012)
  • Postinflammatory hypopigmentation – seen in patients up to two years after a laser treatment.  Occurs in up to 20% of patients with photo-aged skin (Gold 2001).

Light based therapy is not for all skin types.  For example, the indications for use cleared by the FDA may put limits on the skin types that may be treated with a fractional laser.  For example, the indications for use may prohibit the use of the laser on Fitzpatrick 4, 5 , and 6 (darker skin colors), for example: “The EXELO2 with the fractional scanning unit is indicated for ablative skin resurfacing in people with skin types 1, 2 or 3 based on Fitzpatrick skin type scale.” K090639.  The fractional holes “drilled” by the laser are a function of skin type, skin thickness, and vascularity.  Dermapen is not affected by skin type as it does not rely on skin color to turn light into heat.
A major complication from light based therapy includes Postinflamatory Hyperpigmentation (PIH) in Oriental, Mediterranean, and African skin types (Yeung et al., 2012; Metelitsa and Alster 2010; Chan et al., 2007).  PIH presents as symmetric hyperpigmented macules and patches on the face.  PIH is one of the most common and distressing pigmentary disorders seen in dermatology clinics.  It is notably difficult to treat and may relapse.  Of course, Dermapen has not reported PIH complications and thus is safe for darker skin (Fabbrocini et al., 2009).